First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2013-06-17
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this trial is to describe the safety and
tolerability of single intravenous (i.v.) and subcutaneous (s.c.) doses of NNC0215-0384 in
subjects with active rheumatoid arthritis (RA) on background methotrexate (MTX) treatment.